KN057 clinical trials
Also written KN057.
How each study uses KN057 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KN057 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KN057
- 4
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Suzhou Alphamab Co., Ltd. (5)
Studies
Open first, then newest update. How each study uses KN057 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety of KN057 Prophylaxis in Patients With Haemophilia A or BRecruitingPhase 3Suzhou Alphamab Co., Ltd.NCT07545395Written as KN057
- KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsNot yet recruitingPhase 2Suzhou Alphamab Co., Ltd.NCT06747416Written as KN057
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsActive, not recruitingPhase 3Suzhou Alphamab Co., Ltd.NCT06569108Written as KN057
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With InhibitorsActive, not recruitingPhase 3Suzhou Alphamab Co., Ltd.NCT06312475Written as KN057
- KN057 Multiple Dose Study in Moderately Severe to Severe HemophiliaCompletedPhase 2Suzhou Alphamab Co., Ltd.NCT05421429Written as KN057 doseⅠ